Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19

Is early remdesivir treatment associated with lower 1-year all-cause graft loss among kidney transplant (KT) recipients with symptomatic COVID-19? This cohort study emulated a target trial using retrospective data from 432 KT recipients, of whom 41% received early remdesivir within 7 days of COVID-19 diagnosis and 59% received no remdesivir. Early remdesivir vs no remdesivir was associated with a statistically significant lower risk of 1-year all-cause graft loss. The findings support timely consideration of remdesivir for eligible KT recipients and suggest that longer-term graft outcomes should be included when evaluating COVID-19 antiviral strategies in this population.

Corresponding Author: To interview Nitipong Permpalung, MD, MPH, email Jessica Frost (jfrost16@jh.edu ).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.